Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Mar 6, 2020 · 10-K · 66 days after period end · 0001493152-20-003534
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$774.44K | -$609.35K | -$633.86K | -$234.34K |
| EPS Diluted | — | — | -$0.02 | -$0.01 |
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2019 · filed Mar 6, 2020 · 66 d after period end
